http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 30 Jun 2025 22:03:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html <p align="justify">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “<strong>Company</strong>”) announces that it will apply to the TSX Venture Exchange (the “<strong>Exchange</strong>”) to amend the terms of certain outstanding warrants and convertible debentures of the Company, as further described herein.</p> <p align="justify"><strong>Convertible Debenture Amendments</strong></p> <p align="justify">The Company intends to file an application with the Exchange to amend the terms of its 12.0% unsecured convertible debentures with an outstanding aggregate principal amount of $1,454,000.00 (the “<strong>Convertible Debentures</strong>”) issued pursuant to the Company’s non-brokered private placement of Convertible http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Announces+Intention+to+Amend+Debentures+and+Warrants/24999870.html Mon, 30 Jun 2025 22:03:00 -0500 7JO A.15381558 A.50208731 O.00506481 O.02555813 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Press+Releases/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html <p align="left">VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today shared a summary of its H1 2025 accomplishments and provided an outline of its strategic objectives for H2 2025 - against the backdrop of a rapidly evolving global AI landscape.</p> <p><strong>A Transformative AI Backdrop</strong><br/>Artificial intelligence is driving a disruptive shift in how new medicines are discovered, tested, and delivered. In just the past month, AstraZeneca (AZN) signed a drug discovery http://www.streetinsider.com/Globe+Newswire/Rakovina+Therapeutics+Highlights+Strong+H1+Progress+and+Unveils+Strategic+Priorities+for+H2+2025/24993358.html Mon, 30 Jun 2025 03:00:00 -0500 7JO A.27235249 A.50208731 O.02555813 O.02564008 O.48931914 RKV